Recursion Announces First Patient Dosed In Phase 2 Clinical Study Of REC-3964, A Potential First-in-class, Oral, Non-antibiotic Small Molecule For Recurrent Clostridioides Difficile Infection

23/10/2024 11:09 AM

Please email to mremsales@bernama.com for full details about this news.

For full news, click here

BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires; www.bernama.com; BERNAMA TV on Astro 502, unifi TV 631 and MYTV 121 channels and BERNAMA Radio on FM93.9 (Klang Valley), FM107.5 (Johor Bahru), FM107.9 (Kota Kinabalu) and FM100.9 (Kuching) frequencies.

Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial

KEYWORDS

MORE NEWS

Recursion Announces First Patient Dosed In Phase 2 Clinical Study Of REC-3964, A Potential First-in-class, Oral, Non-antibiotic Small Molecule For Recurrent Clostridioides Difficile Infection

Bank Indonesia to Freeze Bank Accounts Linked To Online Gambling

LHDN Committed To Improving Tax Compliance Via Audits, probes

Piecemeal Service Payment Case, An Isolated Issue - RTM

General Line	+603 2631 1000 / +603 2693 9933
Bernama.com	+601 6415 2766
Wires	+603 2631 1535 / 1252
Digital Services	+603 2631 1112
PR/MREM Services	+603 2631 1123
Subscription	+603 2631 1510
Bernama TV	+603 2631 1635
Bernama Radio	+603 2692 9739